Amneal Pharmaceuticals Statistics
Share Statistics
Amneal Pharmaceuticals has 476.92M shares outstanding. The number of shares has increased by 49.72% in one year.
| Shares Outstanding | 476.92M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 49.24% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 141.52M |
| Failed to Deliver (FTD) Shares | 89 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 3.54M, so 0.77% of the outstanding shares have been sold short.
| Short Interest | 3.54M |
| Short % of Shares Out | 0.77% |
| Short % of Float | 2.5% |
| Short Ratio (days to cover) | 3.14 |
Valuation Ratios
The PE ratio is -12.65 and the forward PE ratio is 13.03.
| PE Ratio | -12.65 |
| Forward PE | 13.03 |
| PS Ratio | 0.44 |
| Forward PS | 1.2 |
| PB Ratio | 53.7 |
| P/FCF Ratio | 3.84 |
| PEG Ratio | n/a |
Enterprise Valuation
Amneal Pharmaceuticals Inc. has an Enterprise Value (EV) of 3.73B.
| EV / Earnings | -44.39 |
| EV / Sales | 1.56 |
| EV / EBITDA | 9.33 |
| EV / EBIT | 18.24 |
| EV / FCF | 13.49 |
Financial Position
The company has a current ratio of 1.63, with a Debt / Equity ratio of 139.05.
| Current Ratio | 1.63 |
| Quick Ratio | 0.94 |
| Debt / Equity | 139.05 |
| Total Debt / Capitalization | 99.29 |
| Cash Flow / Debt | 0.13 |
| Interest Coverage | 0.97 |
Financial Efficiency
Return on equity (ROE) is -4.25% and return on capital (ROIC) is 8.92%.
| Return on Equity (ROE) | -4.25% |
| Return on Assets (ROA) | -0.02% |
| Return on Capital (ROIC) | 8.92% |
| Revenue Per Employee | 304.92K |
| Profits Per Employee | -10.70K |
| Employee Count | 7.85K |
| Asset Turnover | 0.69 |
| Inventory Turnover | 2.71 |
Taxes
| Income Tax | 8.45M |
| Effective Tax Rate | -0.21 |
Stock Price Statistics
The stock price has increased by 46.92% in the last 52 weeks. The beta is 1.18, so Amneal Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.18 |
| 52-Week Price Change | 46.92% |
| 50-Day Moving Average | 8.23 |
| 200-Day Moving Average | 7.53 |
| Relative Strength Index (RSI) | 46.05 |
| Average Volume (20 Days) | 1.08M |
Income Statement
In the last 12 months, Amneal Pharmaceuticals had revenue of 2.39B and earned -83.99M in profits. Earnings per share was -0.48.
| Revenue | 2.39B |
| Gross Profit | 820.57M |
| Operating Income | 204.37M |
| Net Income | -83.99M |
| EBITDA | 399.76M |
| EBIT | 204.37M |
| Earnings Per Share (EPS) | -0.48 |
Balance Sheet
The company has 91.54M in cash and 2.75B in debt, giving a net cash position of -2.66B.
| Cash & Cash Equivalents | 91.54M |
| Total Debt | 2.75B |
| Net Cash | -2.66B |
| Retained Earnings | -490.18M |
| Total Assets | 3.46B |
| Working Capital | 418.08M |
Cash Flow
In the last 12 months, operating cash flow was 345.58M and capital expenditures -69.19M, giving a free cash flow of 276.39M.
| Operating Cash Flow | 345.58M |
| Capital Expenditures | -69.19M |
| Free Cash Flow | 276.39M |
| FCF Per Share | 1.58 |
Margins
Gross margin is 34.28%, with operating and profit margins of 8.54% and -3.51%.
| Gross Margin | 34.28% |
| Operating Margin | 8.54% |
| Pretax Margin | -1.68% |
| Profit Margin | -3.51% |
| EBITDA Margin | 16.7% |
| EBIT Margin | 8.54% |
| FCF Margin | 11.55% |
Dividends & Yields
AMRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -6.11% |
| FCF Yield | 7.37% |
Analyst Forecast
The average price target for AMRX is $10, which is 27.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 27.2% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | 1.55 |
| Piotroski F-Score | 5 |